BACKGROUND Chronic myelomonocytic leukemia(CMML),a rare clonal hematopoietic stem cell disorder characterized by myelodysplastic syndrome and myeloproliferative neoplasms,has a generally poor prognosis,and easily prog...BACKGROUND Chronic myelomonocytic leukemia(CMML),a rare clonal hematopoietic stem cell disorder characterized by myelodysplastic syndrome and myeloproliferative neoplasms,has a generally poor prognosis,and easily progresses to acute myeloid leukemia.The simultaneous incidence of hematologic malignancies and solid tumors is extremely low,and CMML coinciding with lung malignancies is even rarer.Here,we report a case of CMML,with ASXL1 and EZH2 gene mutations,combined with non-small cell lung cancer(lung squamous cell carcinoma).CASE SUMMARY A 63-year-old male,suffering from toothache accompanied by coughing,sputum,and bloody sputum for three months,was given a blood test after experiencing continuous bleeding resulting from a tooth extraction at a local hospital.Based on morphological results,the patient was diagnosed with CMML and bronchoscopy was performed in situ to confirm the diagnosis of squamous cell carcinoma in the lower lobe of the lung.After receiving azacitidine,programmed cell death protein 1,and platinum-based chemotherapy drugs,the patient developed severe myelosuppression and eventually fatal leukocyte stasis and dyspnea.CONCLUSION During the treatment and observation of CMML and be vigilant of the growth of multiple primary malignant tumors.展开更多
目的探讨EZH2(enhancer of zeste homolog 2,EZH2)基因在肾透明细胞癌中的表达及其临床意义。方法采用免疫组织化学法分别检测正常肾脏组织(8例)及肾透明细胞癌标本(58例)中EZH2蛋白的表达。结果正常肾脏组织与肾透明细胞癌标本EZH2蛋...目的探讨EZH2(enhancer of zeste homolog 2,EZH2)基因在肾透明细胞癌中的表达及其临床意义。方法采用免疫组织化学法分别检测正常肾脏组织(8例)及肾透明细胞癌标本(58例)中EZH2蛋白的表达。结果正常肾脏组织与肾透明细胞癌标本EZH2蛋白表达率分别为12.5%(1/8)、74.1%(43/58)(P<0.05)。肾透明细胞癌标本中,局部进展性肾癌(Ⅲ)与转移性肾癌(Ⅳ)EZH2蛋白表达明显高于局限性肾癌(Ⅰ+Ⅱ)(P<0.05);高分化肾癌、中分化肾癌及低分化肾癌EZH2蛋白表达不具有显著性差异。结论EZH2在肾透明细胞癌明显高表达,提示其与肾透明细胞癌的发生、发展密切相关,对于肾透明细胞癌的早期诊断及判断预后可能有重要的意义。展开更多
文摘BACKGROUND Chronic myelomonocytic leukemia(CMML),a rare clonal hematopoietic stem cell disorder characterized by myelodysplastic syndrome and myeloproliferative neoplasms,has a generally poor prognosis,and easily progresses to acute myeloid leukemia.The simultaneous incidence of hematologic malignancies and solid tumors is extremely low,and CMML coinciding with lung malignancies is even rarer.Here,we report a case of CMML,with ASXL1 and EZH2 gene mutations,combined with non-small cell lung cancer(lung squamous cell carcinoma).CASE SUMMARY A 63-year-old male,suffering from toothache accompanied by coughing,sputum,and bloody sputum for three months,was given a blood test after experiencing continuous bleeding resulting from a tooth extraction at a local hospital.Based on morphological results,the patient was diagnosed with CMML and bronchoscopy was performed in situ to confirm the diagnosis of squamous cell carcinoma in the lower lobe of the lung.After receiving azacitidine,programmed cell death protein 1,and platinum-based chemotherapy drugs,the patient developed severe myelosuppression and eventually fatal leukocyte stasis and dyspnea.CONCLUSION During the treatment and observation of CMML and be vigilant of the growth of multiple primary malignant tumors.
文摘目的探讨EZH2(enhancer of zeste homolog 2,EZH2)基因在肾透明细胞癌中的表达及其临床意义。方法采用免疫组织化学法分别检测正常肾脏组织(8例)及肾透明细胞癌标本(58例)中EZH2蛋白的表达。结果正常肾脏组织与肾透明细胞癌标本EZH2蛋白表达率分别为12.5%(1/8)、74.1%(43/58)(P<0.05)。肾透明细胞癌标本中,局部进展性肾癌(Ⅲ)与转移性肾癌(Ⅳ)EZH2蛋白表达明显高于局限性肾癌(Ⅰ+Ⅱ)(P<0.05);高分化肾癌、中分化肾癌及低分化肾癌EZH2蛋白表达不具有显著性差异。结论EZH2在肾透明细胞癌明显高表达,提示其与肾透明细胞癌的发生、发展密切相关,对于肾透明细胞癌的早期诊断及判断预后可能有重要的意义。
